Specifically　capturing　and　restraining　residual　circulating　tumor　cells　(CTCs)　in　cancer　patients　are　the　sine　qua　non　for　safely　and　effectively　preventing　cancer　metastasis,　to　which　the　current　chemotherapy　has　been　limited　due　to　its　toxicity.　Moreover,　because　of　CTCs＇　rarity　and　low　activity,　the　current　technology　for　capturing　CTCs　based　solely　on　a　single　surface　biomarker　has　limited　capacity　and　is　used　mainly　for　in　vitro　diagnosis.　Here,　it　is　possible　to　sequentially　conjugate　two　CTCs　antibodies　(aEpCAM　and　aSlex)　to　the　functionalized　dendrimers　to　specifically　capture　human　hepatocellular　CTCs　in　both　artificial　and　clinical　patient　blood　samples,　and　restrain　their　activities.　The　molecular　entities　of　the　conjugates　are　demonstrated　by　various　means.　The　dual　antibody　conjugate　captured　CTCs　threefold　more　than　the　single　counterparts　from　the　high　concentrations　of　interfering　red　blood　cells　or　leukocytes,　as　well　as　from　the　blood　of　liver　cancer　patients,　and　exhibits　the　superiority　to　their　single　counterparts　in　down-regulating　the　captured　CTCs.　These　results　collectively　provide　the　strong　evidence　that　two　antibodies　can　be　compatibly　conjugated　to　a　nanomaterial,　resulting　in　an　enhanced　specificity　in　restraining　CTCs　in　blood.